A detailed history of Fermata Advisors, LLC transactions in Inmune Bio, Inc. stock. As of the latest transaction made, Fermata Advisors, LLC holds 42,730 shares of INMB stock, worth $263,644. This represents 0.05% of its overall portfolio holdings.

Number of Shares
42,730
Previous 34,140 25.16%
Holding current value
$263,644
Previous $301,000 23.59%
% of portfolio
0.05%
Previous 0.07%

Shares

12 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Oct 09, 2024

BUY
$4.86 - $9.86 $41,747 - $84,697
8,590 Added 25.16%
42,730 $230,000
Q2 2024

Jul 12, 2024

BUY
$7.15 - $11.84 $19,226 - $31,837
2,689 Added 8.55%
34,140 $301,000
Q1 2024

Apr 12, 2024

BUY
$10.53 - $14.01 $21,323 - $28,370
2,025 Added 6.88%
31,451 $369,000
Q4 2023

Jan 19, 2024

SELL
$6.6 - $11.52 $180,021 - $314,219
-27,276 Reduced 48.1%
29,426 $331,000
Q3 2023

Nov 06, 2023

BUY
$6.61 - $10.9 $374,800 - $618,051
56,702 New
56,702 $383,000
Q4 2022

Feb 13, 2023

BUY
$6.13 - $7.96 $1,839 - $2,388
300 Added 1.23%
24,611 $156,000
Q3 2022

Nov 14, 2022

BUY
$6.04 - $10.44 $1,812 - $3,132
300 Added 1.25%
24,311 $151,000
Q2 2022

Aug 09, 2022

BUY
$5.48 - $8.97 $24,249 - $39,692
4,425 Added 22.59%
24,011 $212,000
Q1 2022

Apr 22, 2022

BUY
$6.42 - $11.39 $10,471 - $18,577
1,631 Added 9.08%
19,586 $165,000
Q4 2021

Feb 02, 2022

BUY
$9.97 - $20.38 $51,096 - $104,447
5,125 Added 39.95%
17,955 $183,000
Q3 2021

Oct 29, 2021

BUY
$14.13 - $27.85 $15,260 - $30,078
1,080 Added 9.19%
12,830 $249,000
Q2 2021

Aug 10, 2021

BUY
$9.29 - $19.33 $109,157 - $227,127
11,750 New
11,750 $206,000

Others Institutions Holding INMB

About Inmune Bio, Inc.


  • Ticker INMB
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 17,946,000
  • Market Cap $111M
  • Description
  • INmune Bio, Inc., a clinical-stage immunotherapy company, focuses on developing drugs to reprogram the patient's innate immune system to treat disease. The company develops and commercializes product candidates to treat hematologic malignancies, solid tumors, and chronic inflammation. Its development programs include INKmune, which focuses on tr...
More about INMB
Track This Portfolio

Track Fermata Advisors, LLC Portfolio

Follow Fermata Advisors, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Fermata Advisors, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Fermata Advisors, LLC with notifications on news.